ELDN vs. GYRE, OCS, REPL, COGT, DAWN, EOLS, AVDL, AVXL, PHVS, and CDMO
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Gyre Therapeutics (GYRE), Oculis (OCS), Replimune Group (REPL), Cogent Biosciences (COGT), Day One Biopharmaceuticals (DAWN), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Anavex Life Sciences (AVXL), Pharvaris (PHVS), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs.
Gyre Therapeutics (NASDAQ:GYRE) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
Eledon Pharmaceuticals has a consensus target price of $12.50, suggesting a potential upside of 260.23%. Given Eledon Pharmaceuticals' higher possible upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Gyre Therapeutics.
Gyre Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Gyre Therapeutics' return on equity of -118.43% beat Eledon Pharmaceuticals' return on equity.
Gyre Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 19.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Eledon Pharmaceuticals received 27 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 73.68% of users gave Eledon Pharmaceuticals an outperform vote.
In the previous week, Gyre Therapeutics had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 13 mentions for Gyre Therapeutics and 12 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.30 beat Gyre Therapeutics' score of 0.23 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.
Summary
Gyre Therapeutics beats Eledon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 3/26/2025 by MarketBeat.com Staff
